Merck KGaA picks a new R&D chief Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 5 September, 2025

Join Endpoints News as we celebrate the exceptional women shaping biopharma’s future — visionary leaders and trailblazing executives driving transformative change in R&D. Don’t miss our new virtual networking opportunity — sign up today.

news Hengrui does another US deal, this time in Cytokinetics' cardio arena BioNTech and DualityBio’s ADC hits in late-stage breast cancer trial in China Peer Review Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves In a first, FDA publishes complete response letters for ongoing drug applications

Sep 09 11:30am ET How ctDNA can assist in critical nonoperative management decisions sponsored by Haystack MRD Sep 23 11:00am ET Data you can trust: Setting the bar for ML/LLM-extracted real-world data sponsored by Flatiron Sep 25 11:00am ET Leveraging acoustic focusing for fast and precise high-parameter flow cytometry panels sponsored by Thermo Fisher Oct 02 10:30am ET Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery sponsored by Lilly Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Big Pharma is doubling down. Startups are going all in. Who’s actually making AI work in drug R&D? Join the debate with expert discussions and insights you won’t want to miss. Register today.

ENDPOINTS PHARMA RFK Jr. spars with senators over CDC turmoil, limited Covid vaccine approvals FDA delays decision on Agios drug in thalassemia over liver safety J&J, Bristol Myers lose appeals cases challenging Medicare price negotiation AstraZeneca ends manufacturing license at Indian plant as it exits the site

in case you missed it 1. Sanofi's stock take a hit from subpar Phase 3 eczema data 2. Immunovant reports more good data with first-gen FcRn drug, but says it's still focused on follow-up compound 3. MindMed publishes Phase 2b LSD data, with execs bullish about distinction from Spravato 4. AC Immune culls pipeline, lays off 30% of staff to extend cash runway further into 2027 5. Atlas Venture raises $400M to support existing portfolio biotechs 6. Enveda collects another $150M for I&I drug, sprawling pipeline of preclinical assets